MedTrace Logo

High-dose, Short-term Steroid and Low-dose Long-term Steroid Use in ARDS Caused by COVID-19

NCT05047874 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2021-09-17

No results posted yet for this study

Summary

In this study, we aimed to compare, retrospectively, the 15-day continuous hemodynamic, laboratory and clinical course of COVID 19 patients to whom we administered short-term (3 days) high-dose (1000 mg) systemic methylprednisolone with those to whom low-dose long-term (2x 40 mg) systemic methylprednisolone was administered.

Conditions

  • Short-term (3 Days) High-dose (1000 mg) Systemic Methylprednisolone

Interventions

BEHAVIORAL

systemic methylprednisolone

short-term (3 days) high-dose (1000 mg) systemic methylprednisolone and low-dose long-term (2x 40 mg) systemic methylprednisolone

Sponsors & Collaborators

  • Biruni University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
105 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-20
Primary Completion
2021-10-20
Completion
2021-10-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05047874 on ClinicalTrials.gov